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Dyslipidemia and Changes in Lipid Proﬁles
Associated With Rheumatoid Arthritis and
Initiation of Anti–Tumor Necrosis Factor Therapy
JEFFREY R. CURTIS,1 ANI JOHN,2 AND ONUR BASER3
Objective. To investigate the frequency of lipid testing in clinical practice and to explore the relationship between
rheumatoid arthritis (RA), dyslipidemia, and other cardiovascular (CV) risk factors with RA treatment.
Methods. Patients in this retrospective database study were ages >18 years and had >2 physician diagnoses for RA or
osteoarthritis (OA; comparator group) between March 2004 and March 2008. Outcomes of interest included the percent-
age of RA and OA patients receiving lipid tests, lipid proﬁles (total cholesterol, low-density lipoprotein [LDL] cholesterol,
and high-density lipoprotein [HDL] cholesterol) of RA versus OA patients, and lipid proﬁles of RA patients before and
after initiation with a tumor necrosis factor (TNF) inhibitor. We used multivariable regression to control potential
confounders between the cohorts.
Results. Over a median >2-year followup, fewer RA patients than OA patients had >1 lipid test (62.0% [95% conﬁdence
interval (95% CI) 61.5–62.5] versus 69.8% [95% CI 69.5–70.1]). Mean total cholesterol and LDL cholesterol were each
4 mg/dl lower in the RA cohort (P < 0.0001); HDL cholesterol was similar between the cohorts. Across the RA cohort,
25.2% of patients had suboptimal LDL cholesterol levels (>130 mg/dl). Among RA patients not receiving lipid-lowering
therapy who initiated TNF inhibitor therapy (n  96), mean total cholesterol and LDL cholesterol increased by 5.4 and
4.0 mg/dl, respectively.
Conclusion. Patients with RA were less likely to be tested for hyperlipidemia and had more favorable lipid proﬁles than
patients with OA. TNF inhibitor therapy modestly increased all lipid parameters. Additional studies are needed to
determine the effect of traditional CV risk factors and inﬂammation and the impact of biologic agents on CV outcomes in
RA patients.
INTRODUCTION
Patients with rheumatoid arthritis (RA) have higher rates
of morbidity and mortality than the general population,
which is highly attributed to an increased risk of cardio-
vascular disease (CVD) among RA patients (1,2). The in-
creased risk of CVD appears to be linked to coronary ath-
erosclerosis (3,4) and may be directly caused by chronic
inﬂammation or secondarily caused by physical inactivity
and medications used to treat RA (5). Not surprisingly, RA
treatment guidelines reﬂect this increased cardiovascular
(CV) risk among patients with RA. Evidence-based and
expert opinion–based recommendations from the Euro-
pean League Against Rheumatism for the screening and
management of RA patients include annual CV risk assess-
ment, management of identiﬁed CV risk factors, and ag-
gressive suppression of the inﬂammatory process to fur-
ther lower the CV risk (6).
Lipid levels appear to be altered as a result of RA disease
activity. Data on total cholesterol and low-density lipopro-
tein (LDL) cholesterol levels in patients with RA are con-
ﬂicting: some studies demonstrate similar (7) or lower (8)
levels of total cholesterol, whereas others demonstrate in-
creased levels of total cholesterol and LDL cholesterol in
patients with early RA (9). Although reports on lipid pro-
ﬁles in RA patients vary, growing evidence suggests that
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patients with untreated RA have reduced total cholesterol,
LDL cholesterol, and high-density lipoprotein (HDL) cho-
lesterol levels (8,10,11). Regardless of the total cholesterol
changes in RA patients, several studies support the notion
that RA leads to a more atherogenic lipid proﬁle (ratio of
total cholesterol to HDL cholesterol), which is correlated
with disease activity and improves after treatment with
antirheumatic medications (7–9,12).
Inﬂammation is a common denominator in both RA and
atherosclerosis. A growing body of evidence supports the
involvement of common proinﬂammatory cytokines, such
as macrophage migration inhibitory factor, interleukin-1
(IL-1), IL-6, and tumor necrosis factor  (TNF), in the
development and progression of both RA and atheroscle-
rosis (3,13). Several studies have demonstrated that the
use of disease-modifying antirheumatic drugs and biologic
agents that affect these cytokines reduces inﬂammation in
patients with RA and may be associated with a reduced
risk of CVD (12,14–20).
Given that inﬂammation in RA patients alters the lipid
proﬁle, it is not surprising that treatment to control in-
ﬂammation in RA patients may also affect lipid levels. A
recent meta-analysis of 24 observational studies evaluating
the effect of TNF inhibitor therapy on lipids in patients
with RA showed a small trend in an increase in total
cholesterol, mostly due to an increase in HDL cholesterol
levels (21). In light of uncertainties regarding the relation-
ship between RA, lipid proﬁles, and potent antiinﬂam-
matory medications such as TNF inhibitor therapy, we
used a large population-based database to investigate the
frequency of lipid testing in clinical practice and to ex-
plore the relationship between RA, dyslipidemia, CVD risk
factors, and RA treatment. The primary objective of this
study was to evaluate the proportion of RA patients receiv-
ing lipid testing and the frequency of testing compared to
controls (patients with osteoarthritis [OA]). We hypothe-
sized that patients with RA would be tested less frequently
than patients with OA. Secondary objectives included
comparing lipid levels in RA patients versus controls (OA
patients) among patients tested for hyperlipidemia and
describing changes in lipid levels in patients with RA who
initiated therapy with a TNF inhibitor.
MATERIALS AND METHODS
Patient identiﬁcation. A retrospective analysis was
conducted using data from the OptumInsight Impact data-
base. This database includes medical claims, pharmacy
claims, laboratory data, and patient eligibility data for
86.4 million covered patients, of which 63.7 million (74%)
have pharmacy beneﬁts and 12.6 million have laboratory
results. The database includes patients ages65 years, all of
whom are covered by standard commercial or managed
care plans. The Impact database is derived from 46 health
plans located across all census regions in the US (predom-
inantly located in the North, North Central, and Atlantic
regions).
Patients were included in the study if they were age18
years and had 2 separate physician diagnoses (2
months apart) for RA (International Classiﬁcation of Dis-
eases, Ninth Revision, Clinical Modiﬁcation [ICD-9-CM]
code 714.xx) or for OA (ICD-9-CM code 715.xx) between
March 2004 and March 2008 (Table 1). Patients were ex-
cluded from the study if they had a diagnosis for any other
autoimmune inﬂammatory disease at any time during the
study observation period (see Supplementary Table 1, avail-
able in the online version of this article at http://online
library.wiley.com/journal/10.1002/(ISSN)2151-4658). Pa-
tients with OA were chosen as a comparator group for
patients with RA because OA is a chronic condition that
affects joints and may limit physical functioning, but does
not have the systemic inﬂammatory features more com-
mon to RA. Furthermore, OA patients were expected to be
more comparable to RA patients, given a higher expected
prevalence of use of nonsteroidal antiinﬂammatory drugs
(a recognized CV risk factor that might impact CV risk
assessment) and more frequent contact with the medical
system (which can motivate more use of appropriate
screening tests) compared to the general population with-
out chronic medical conditions. Additional study eligibil-
ity requirements and study design details that varied by
the 3 study objectives are listed in Table 1.
All measures of a complete lipid panel, i.e., total cho-
lesterol, HDL cholesterol, LDL cholesterol, and triglycer-
ides, that occurred at any time during the observation
period were evaluated in this study in time windows
speciﬁc for each objective (Table 1). Classiﬁcation of lipid
levels was based on the Adult Treatment Panel III (ATP-
III) cholesterol management guidelines (22). Use of lipid-
lowering medications, including niacin, ﬁbric acid de-
rivatives, bile acid binding resins, cholesterol absorption
inhibitors, and hydroxymethylglutaryl-coenzyme A reduc-
tase inhibitors, was also evaluated in this study.
Statistical analyses. All study variables, including
baseline and outcome measures, were analyzed descrip-
tively. Dichotomous variables were expressed as numbers
and percentages and continuous variables were expressed
as means  SDs, medians, or percentiles.
For dichotomous variables, P values were calculated
using the Mann-Whitney U test, and for continuous vari-
ables, P values were calculated using t-tests. Multivariable
Signiﬁcance & Innovations
● Our retrospective analysis of a representative US
database demonstrated that patients with rheuma-
toid arthritis (RA) are signiﬁcantly less likely to be
tested for hyperlipidemia than controls (patients
with osteoarthritis).
● Approximately 25% of patients with RA have sub-
optimal low-density lipoprotein cholesterol levels
according to the Adult Treatment Panel III choles-
terol management guidelines.
● Initiation of anti–tumor necrosis factor therapy in-
creased total cholesterol levels by approximately
5 mg/dl among RA patients not receiving treat-
ment with lipid-lowering agents.
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regression was used to control for confounders and to
increase the efﬁciency of the estimators. The outcome
variables and covariates used to control for baseline dif-
ferences varied between objectives and are described in
Table 1.
RESULTS
Objective 1: frequency of lipid testing, comparing RA
versus OA patients. The sample of individuals initially
meeting eligibility requirements included 30,586 patients
with an RA diagnosis and 107,534 patients with an OA
diagnosis (control group). Characteristics of each group at
baseline, deﬁned as 6 months prior to RA or OA diagnosis,
are shown in Table 2. The groups were signiﬁcantly dif-
ferent in most covariates; therefore, regression analysis
was performed to control for these differences.
Over a median followup period of 2.2 years (interquar-
tile range [IQR] 1.6–2.8 years) for patients in the RA group
and 2.5 years (IQR 1.9–3.1 years) for patients in the OA
group, fewer RA patients than OA patients had 1 lipid
test (62.0% [95% conﬁdence interval (95% CI) 61.5–62.5]
versus 69.8% [95% CI 69.5–70.1]). There were somewhat
fewer patients in the RA group than in the OA group who
had 1 test for total cholesterol (59.8% [95% CI 59.3–
60.3] versus 69.0% [95% CI 68.7–69.3]), HDL cholesterol
(57.2% [95% CI 56.6–57.8] versus 66.4% [95% CI 66.1–
66.7]), LDL cholesterol (58.6% [95% CI 58.0–59.2] versus
68.4% [95% CI 68.1–68.7]), or triglycerides (59.1% [95%
CI 58.5–59.7] versus 68.4% [95% CI 68.1–68.7]). Further-
more, the analysis of the risk-adjusted differences in the
number of tests revealed that among patients who received
a lipid test, slightly fewer tests were performed for RA
patients than OA patients (total cholesterol: 2.0 [95% CI
1.8–2.2] versus 2.9 [95% CI 2.6–3.2], HDL cholesterol: 1.8
[95% CI 1.7–1.9] versus 2.7 [95% CI 2.5–2.9], LDL choles-
terol: 1.9 [95% CI 1.4–2.4] versus 2.9 [95% CI 2.5–3.3], and
triglycerides: 1.0 [95% CI 0.8–1.2] versus 2.9 [95% CI
2.7–3.2]). Because followup time was somewhat longer
for OA patients versus RA patients, a subgroup analysis
restricted the cohort to patients with 18 months of ob-
servation time after the start of followup and ﬁxed the
ascertainment period to these 18 months. Among this sub-
group (71% of the RA cohort and 68% of the OA cohort),
RA patients were less likely compared to OA patients to
receive any total cholesterol testing (56% [95% CI 53–59]
versus 67% [95% CI 63–71]).
Objective 2: comparison of lipid levels in RA versus
OA patients. From the initial sample size of 136,996 RA
patients, and based on the availability of laboratory data
in the database, 12,319 (9.0%) were eligible for the lipid
level objective analysis compared with the 29,621 patients
(15.3%) from the 194,192 OA controls. Similar to the study
population for objective 1, there were signiﬁcant differ-
ences among eligible RA patients and OA patients at base-
line (Table 3).
Multivariable-adjusted regression analysis was per-
formed to assess risk-adjusted lipid levels and CVD-related
comorbidity prevalence. Mean total cholesterol, LDL cho-
lesterol, and triglyceride levels were signiﬁcantly lower
in the RA cohort than in the OA cohort (total cholesterol:
195 mg/dl [95% CI 191–199] versus 199 mg/dl [95% CI
192–205], LDL cholesterol: 112 mg/dl [95% CI 111–113]
versus 116 mg/dl [95% CI 114–118], and triglycerides:
132 mg/dl [95% CI 129–135] versus 138 mg/dl [95% CI
136–140]; P  0.0001 for all comparisons), whereas HDL
cholesterol levels were marginally higher for the RA co-
hort relative to the OA cohort (56.8 mg/dl versus 56.1 mg/
dl; P  0.02). Furthermore, signiﬁcantly fewer RA patients
than OA patients had borderline high or high total choles-
terol and LDL cholesterol levels, based on ATP-III lipid
Table 2. Demographic and clinical characteristics of
patients included in the lipid testing sample (objective 1)
measured during the 6-month baseline period*
RA patients
(n  30,586)
OA patients
(n  107,534)
Female sex 22,658 (74.1) 62,689 (58.3)
Age group, years
18–49 13,883 (45.4) 27,430 (25.5)
50–64 13,560 (44.3) 58,716 (54.6)
65–74 2,124 (6.9) 12,289 (11.4)
75–84 1,019 (3.3) 9,099 (8.5)
Age, mean  SD years 50.2  12.0 56.1  10.6
Capitated insurance 7,683 (25.1) 40,499 (37.7)
Census region
Midwest 4,389 (14.4) 14,208 (13.2)
Northeast 10,846 (35.5) 52,408 (48.7)
South 11,778 (38.5) 30,069 (28.0)
West 3,569 (11.7) 10,815 (10.1)
Comorbidities and scores
CCI score (45), mean  SD 1.1  0.9 0.4  0.9
Chronic Disease Score
(46), mean  SD
2.5  3.0 2.8  2.9
Fibromyalgia 2,593 (8.5) 5,336 (5.0)
Respiratory infections 7,844 (25.7) 32,472 (30.2)
Diabetes mellitus 1,880 (6.2) 10,385 (9.7)
Obesity 664 (2.2) 4,445 (4.1)
Hypertension 7,077 (23.1) 41,259 (38.4)
Health care utilization,
mean  SD
Inpatient visits 0.1  0.3 0.1  0.3
Physician visits 4.4  6.2 5.9  6.6
Outpatient visits 1.2  2.8 1.7  3.4
ER visits 0.2  1.3 0.3  1.3
RA-related medications
Noncytotoxic DMARDs† 3,498 (11.4) 399 (0.4)
Cytotoxic DMARDs‡ 795 (2.6) 680 (0.6)
Methotrexate 3,764 (12.3) 118 (0.1)
Corticosteroids 7,421 (24.3) 16,772 (15.6)
NSAIDs 13,047 (42.7) 50,215 (46.7)
Lipid-lowering medications 3,570 (11.7) 26,896 (25.0)
* Values are the number (percentage) unless otherwise indicated.
RA  rheumatoid arthritis; OA  osteoarthritis; CCI  Charlson
Comorbidity Index; ER  emergency room; DMARDs  disease-
modifying antirheumatic drugs; NSAIDs  nonsteroidal antiinﬂam-
matory drugs.
† Gold compounds, penicillamine, chloroquine, hydroxychloro-
quine, and sulfasalazine.
‡ Azathioprine, cyclosporine, cyclophosphamide, and leﬂunomide.
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classiﬁcation levels (P  0.0001) (Figure 1). Patients with
RA were signiﬁcantly less likely than patients with OA to
have a recorded diagnosis of hyperlipidemia (33% [95%
CI 28–35] versus 45% [95% CI 41–48]) and hypertension
(45% [95% CI 41–49] versus 54% [95% CI 49–56]; P 
0.0001 for both).
Objective 3: comparison of lipid levels before and after
TNF inhibitor therapy in RA patients. A total of 1,393
patients with RA were eligible for the analysis of changes
in lipid levels after TNF inhibitor therapy initiation. Of
these patients, 289 had a lipid test within 90 days preced-
ing and following TNF inhibitor initiation, 477 patients
had a lipid test within 120 days, and 766 had a test within
180 days of TNF inhibitor initiation. Lipid test results
were further stratiﬁed by use or nonuse of lipid-lowering
medications before and after TNF inhibitor initiation. Pa-
tients were classiﬁed as consistent users (lipid-lowering
medication use before and after TNF inhibitor therapy),
nonusers (no lipid-lowering medication use before or after
Table 3. Demographic and clinical characteristics of patients included in the lipid level
sample (objective 2) measured during the 6-month baseline period*
RA patients
(n  12,319)
OA patients
(n  29,621)
Female sex 9,357 (76.0) 18,410 (62.8)
Age group, years
18–49 3,895 (31.6) 5,216 (17.8)
50–64 6,565 (53.3) 16,429 (56.0)
65–74 1,287 (10.5) 4,291 (14.6)
75–84 572 (4.6) 3,400 (11.6)
Age, mean  SD years 54.2  11.0 58.7  10.3
Capitated insurance 4,208 (34.2) 11,953 (40.8)
Census region
Midwest 1,165 (9.5) 3,100 (10.6)
Northeast 4,872 (39.6) 10,809 (36.9)
South 5,595 (45.4) 13,981 (47.7)
West 685 (5.6) 1,439 (4.9)
Comorbidities and scores
CCI score (45), mean  SD 1.2  1.1 0.5  1.0
Chronic Disease Score (46), mean  SD 4.5  3.5 3.1  3.0
Fibromyalgia 912 (7.4) 1,262 (4.3)
Respiratory infections 4,367 (35.5) 9,944 (33.9)
Diabetes mellitus 1,599 (13.0) 4,242 (14.5)
Obesity 330 (2.7) 1,295 (4.4)
Hypertension 5,379 (43.7) 15,603 (53.2)
Polycystic ovarian disease 18 (0.2) 12 (0.0)
Coronary artery disease 943 (7.7) 2,538 (8.7)
Heart failure 236 (1.9) 632 (2.2)
Hyperlipidemia 6,073 (49.3) 16,635 (56.7)
Lipid levels, mean  SD mg/dl
Total cholesterol 196.2  36.4 198.7  37.8
HDL cholesterol 56.6  15.9 55.2  16.1
LDL cholesterol 113.0  31.7 115.9  33.3
Triglycerides 133.1  66.8 138.5  68.8
Health care utilization
Inpatient visits 0.0  0.2 0.1  0.3
Physician visits 4.2  6.0 5.8  6.5
Outpatient visits 1.3  2.2 1.8  3.5
ER visits 0.2  1.2 0.3  1.2
RA-related medications
DMARD only 4,439 (36.0) 0 (0.0)
Non–TNF inhibitor only 3 (0.0) 1 (0.0)
Non–TNF inhibitor and DMARDs 13 (0.1) 0 (0.0)
TNF inhibitor only 819 (6.7) 0 (0.0)
TNF inhibitor and DMARDs 1,231 (10.0) 0 (0.0)
Corticosteroids 4,166 (33.8) 4,587 (15.6)
NSAIDs 6,639 (53.9) 12,849 (43.8)
Lipid-lowering medications 3,294 (26.7) 8,678 (29.6)
* Values are the number (percentage) unless otherwise indicated. RA  rheumatoid arthritis; OA 
osteoarthritis; CCI  Charlson Comorbidity Index; HDL  high-density lipoprotein; LDL  low-density
lipoprotein; ER  emergency room; DMARD  disease-modifying antirheumatic drug; TNF  tumor
necrosis factor; NSAIDs  nonsteroidal antiinﬂammatory drugs.
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Figure 1. Proportions of rheumatoid arthritis (RA) and osteoarthritis (OA) patients in various lipid categories based on Adult Treatment
Panel III (ATP-III) classiﬁcations. RA and OA cohorts were adjusted using multivariable regression based on factors listed in Table 1. Error
bars show the 95% conﬁdence interval of the mean. LDL  low-density lipoprotein; HDL  high-density lipoprotein.
Figure 2. Changes in lipid levels after tumor necrosis factor inhibitor (TNFi) initiation in patients with rheumatoid arthritis. Includes
patients who underwent lipid testing within 90 days before and after TNFi initiation. Not all patients underwent the complete set of lipid
tests (e.g., patients might have undergone only total cholesterol testing but not high-density lipoprotein [HDL] cholesterol or low-density
lipoprotein [LDL] cholesterol testing). A linear regression model was used to control for the factors listed in Table 1. *  P  0.0001; † 
P  0.01 for the null hypothesis that there was no change in lipid values after TNFi initiation.
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TNF inhibitor therapy), or mixed users (lipid-lowering
medication therapy either before or after TNF inhibitor
therapy, but not both). Mixed lipid-lowering medication
users’ results were not reported due to an inadequate sam-
ple size to characterize the various patterns of use with
these agents. Furthermore, we did not observe any patients
who started TNF inhibitor therapy, then were tested for
hyperlipidemia but who did not have a result available in
the data, initiated a lipid-lowering medication, and then
were retested and had lipid results available.
We identiﬁed 289 patients with paired lipid levels
within 90 days preceding and following the start of TNF
inhibitor treatment (mean 65 days between the paired
lipid tests). Among nonusers of lipid-lowering medica-
tions starting therapy with a TNF inhibitor (n  96), mean
HDL cholesterol, total cholesterol, and LDL cholesterol
levels increased modestly (HDL cholesterol: 0.9 mg/dl
[95% CI 0.1–1.6], total cholesterol: 5.4 mg/dl [95% CI
2.6–18.3], and LDL cholesterol: 4.0 mg/dl [95% CI 0.3–
7.7]) (Figure 2). Mean triglyceride levels also increased in
these patients (mean change 7.3 mg/dl; P  0.08). Among
consistent lipid-lowering medication users (n  21), HDL
cholesterol levels decreased by a mean of 3.4 mg/dl (95%
CI 2.2–10.0); no signiﬁcant changes were observed in total
cholesterol, LDL cholesterol, and triglyceride levels (Fig-
ure 2). The atherogenic index (ratio of total cholesterol to
HDL cholesterol) decreased in both patients consistently
receiving and not receiving lipid-lowering medications
(3.8 to 3.6 and 3.7 to 3.6, respectively; P  0.08).
The within-person analysis described above was re-
peated for the groups who had lipid testing within 120
and 180 days of TNF inhibitor initiation. Study results
were consistent, with adjusted LDL cholesterol levels con-
sistently higher after TNF inhibitor initiation in patients
not taking lipid-lowering medications, regardless of the
timing of the test (data not shown).
DISCUSSION
This real-world analysis demonstrated that patients with
RA had mean total cholesterol, LDL cholesterol, and tri-
glyceride levels that were lower than patients with OA.
Although RA patients were slightly more likely to be in a
favorable ATP-III category, approximately 25% of RA pa-
tients had suboptimal lipid levels based on current ATP-III
guidelines (22). Among patients with RA initiating TNF
inhibitor therapy and who had their total cholesterol and
LDL cholesterol levels retested within 3 months, mean
total cholesterol and LDL cholesterol levels increased by 5
and 4 mg/dl, respectively, after TNF inhibitor therapy was
initiated. Finally, we observed that while patients with RA
were only slightly less likely to receive any lipid testing
than OA patients, approximately one-third of RA patients
did not receive any testing during the observation period
of more than 2 years.
Among RA patients not receiving lipid-lowering medi-
cations, we observed that treatment with a TNF inhibitor
was associated with modest increases in total cholesterol
and LDL cholesterol levels. This is consistent with results
from other studies that observed increases in lipid levels
after treatment with biologic agents. In a recent meta-
analysis of 24 observational studies evaluating the effect
of TNF inhibitor therapy on lipids in patients with RA, a
small trend of an increase in total cholesterol was observed
(21). Of the 4 controlled studies that measured the athero-
genic index, 1 study found a signiﬁcant increase of 8.9%
in the TNF inhibitor therapy group and a signiﬁcant de-
crease of 10.4% in the control group (23), 2 studies re-
ported nonsigniﬁcant decreases in the TNF inhibitor group
with no changes in the control groups (24,25), and 1 study
reported a signiﬁcant decrease in cases compared to con-
trols, but data were not provided (26). In our study, we
found minimal changes in lipid proﬁles among RA pa-
tients who were treated with lipid-lowering medication
prior to and during TNF inhibitor therapy. However, our
results could not be compared with the meta-analysis,
since no similar subgroup analysis of lipid level changes
among patients receiving lipid-lowering medication treat-
ments was performed (21).
Aside from TNF inhibitors, other biologic agents have
been shown to affect lipid proﬁles. Tocilizumab (TCZ),
which inhibits the proinﬂammatory cytokine IL-6 binding
to its receptors (27), is associated with decreases in inﬂam-
matory markers (28). TCZ is associated with increased
lipid levels in patients with RA (e.g., an increase in LDL
cholesterol of 20 mg/dl among those receiving TCZ 
methotrexate), but has not been associated with an in-
crease in CV events during short-term followup (29–32).
In a recently completed long-term followup study of TCZ
in patients with RA (mean treatment duration 2.4 years),
total cholesterol, HDL cholesterol, LDL cholesterol, and
triglyceride levels increased after 6 weeks of treatment
and remained relatively stable at the elevated level there-
after (31,32).
The clinical importance of lipid levels to CVD risk in
RA is not completely understood. Recent evidence sug-
gests that there may be a paradoxical effect of lipids on
the risk of CVD in RA, where lower and not higher total
cholesterol and LDL cholesterol levels are associated with
an increased CV risk (11). Furthermore, although HDL
cholesterol is generally considered to be cardioprotective,
both through its ability to promote cholesterol efﬂux from
artery cell walls and antiinﬂammatory properties that pro-
tect LDL cholesterol from oxidation, a growing body of
evidence suggests that in inﬂammatory conditions such as
RA and systemic lupus erythematosus, patients have non-
protective “proinﬂammatory HDL,” which promotes accu-
mulation of oxidized phospholipids in LDL cholesterol
(33,34).
Based on what appears to be more favorable total cho-
lesterol and LDL cholesterol distributions in RA patients
compared to OA patients, the results of this analysis sug-
gest that lipid proﬁles in patients with RA only partially
explain the previously observed excess CVD risk associ-
ated with the systemic inﬂammation of RA (35). Other
inﬂammation-induced factors, such as increased oxidative
stress, insulin resistance, endothelial dysfunction, pro-
thrombotic state, and elevated homocysteine levels (36), as
well as noninﬂammatory mechanisms, such as genetic
polymorphism and CV toxicity associated with certain
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antirheumatic drugs (e.g., glucocorticoids), may also con-
tribute to the increased CVD risk in RA (36).
A major strength of this study is that it is based on
real-world clinical practice. The data set closely represents
the US in terms of population age, sex, and geographic
region (37). Comparing the US versus the Impact data set,
the age distributions are as follows: 0–20 years (27% ver-
sus 25%), 21–39 years (27% versus 24%), 40–64 years
(31% versus 40%), and 65 years (13% versus 11%). In
terms of regions, the distributions are as follows: Northeast
(18% versus 29%), Midwest (22% versus 26%), South
(37% versus 37%), and West (23% versus 11%). Similar
proportions of men are in each (49% in the US versus 51%
in the Impact data set).
Conclusions from this study need to be weighed within
the conﬁnes of some limitations of this data source. Clin-
ical data related to risk factors such as smoking, CVD
history, family history of CVD, and blood pressure, as well
as RA disease severity and activity, were not available
in the database. Studies have shown that while some tra-
ditional risk factors (dyslipidemia, family cardiac history,
hypertension, diabetes mellitus, and obesity) impart sim-
ilar risk for a CV event among patients with or without
RA, other traditional CV risk factors (male sex, smoking,
and personal cardiac history) impart signiﬁcantly less rel-
ative CV risk in patients with versus without RA (38).
Beyond traditional CV risk factors, several disease severity
and disease activity markers in RA, such as extraarticular
manifestations, elevated erythrocyte sedimentation rate,
rheumatoid factor seropositivity, higher joint count, and
functional status, correlate with the rate of CVD and major
CV events, including myocardial infarction, congestive
heart failure, and death (4,39–41).
Another limitation of this study is that this analysis did
not investigate longitudinal changes in lipid levels asso-
ciated with TNF inhibitor therapy beyond 180 days. A
study by Popa et al showed that although short-term ef-
fects of TNF inhibitor therapy on lipids seemed beneﬁcial
and antiatherogenic, the atherogenic index increased after
6 months from the start of therapy. Furthermore, changes
in disease activity and inﬂammatory status were inversely
correlated with changes in total cholesterol and HDL cho-
lesterol levels and positively correlated with the variation
of atherogenic index (42). When evaluated over a longer
period of time, such as 6 months or beyond, inﬂiximab
treatment has been associated with signiﬁcantly increased
levels of total cholesterol and triglycerides, with no change
in HDL cholesterol and LDL cholesterol or atherogenic
indices at 6 months (43). In other studies, RA patients
treated with inﬂiximab had increased lipid levels (total
cholesterol, HDL cholesterol, and LDL cholesterol) ini-
tially, which returned to baseline by 6 months to 1 year of
treatment (except for total cholesterol levels, which re-
mained increased in 1 study) (26,44). The effect of time
was partially addressed in this study by sensitivity analy-
sis in which similar results were obtained when lipid tests
were carried out before or after 120 and 180 days. How-
ever, further investigations into the long-term effect of
TNF inhibitor therapy on lipid levels are needed. Finally,
we excluded patients who initiated lipid-lowering therapy
after initiation of TNF inhibitor therapy and before follow-
up lipid testing was performed (i.e., described as “mixed”
lipid-lowering medication users). While this may have
excluded some individuals with elevated lipid levels,
these patients initiated a lipid-lowering medication prior
to followup lipid testing, avoiding concern for a selection
bias related to the effect of TNF inhibitors on lipids.
In conclusion, patients with RA have a higher mortality
rate than the general population. Much of this risk is due
to CVD. This study showed that in clinical practice, RA
patients were tested for dyslipidemia less frequently than
their counterparts with OA. Furthermore, although pa-
tients with RA tended to have relatively lower lipid levels,
more than 25% of patients had suboptimal lipid levels
based on current ATP-III guidelines. Analysis of lipid lev-
els in RA patients before and after TNF inhibitor therapy
initiation showed modest increases in total cholesterol,
LDL cholesterol, and HDL cholesterol levels among pa-
tients not receiving lipid-lowering medications. Due to the
increased risk of CVD and mortality among patients with
RA, more aggressive and earlier lipid management, includ-
ing greater use of statin therapy, may be appropriate to
reduce CVD among RA patients who have elevated lipid
and C-reactive protein levels. Additional prospective long-
term studies are needed to comprehensively determine the
role of inﬂammation and the impact of biologic agents on
lipid levels and CV outcomes in patients with RA.
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